• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Biote Corp.

    5/18/26 4:30:20 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BTMD alert in real time by email
    8-K
    false 0001819253 0001819253 2026-05-12 2026-05-12
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): May 12, 2026

     

     

    biote Corp.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-40128   85-1791125

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    1875 W. Walnut Hill Ln #100
    Irving, Texas 75038
    (Address of principal executive offices, including zip code)

    (844) 604-1246

    (Registrant’s telephone number, including area code)

    (Former name or former address, if changed since last report)

     

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbols

     

    Name of each exchange

    on which registered

    Class A common stock, par value $0.0001 per share   BTMD   The Nasdaq Stock Market LLC

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    On May 12, 2026, biote Corp., a Delaware corporation (the “Company”), held its 2026 annual meeting of stockholders (the “Annual Meeting”).

    Below are detailed voting results on each matter voted on which are described in more detail in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 2, 2026 (the “Proxy Statement”).

    Proposal 1: Election of Directors

    The Company’s stockholders elected the two individuals listed below to serve as Class I directors until the Company’s 2029 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. The final voting results are as follows:

     

    Nominee    For      Withheld      Broker Non-Votes  

    Andrew R. Heyer

         22,759,692        3,960,800        2,861,704  

    Dana Jacoby

         23,020,635        3,699,857        2,861,704  

    Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm

    The Company’s stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:

     

    For    Against    Abstain    Broker Non-Votes
    29,507,419    67,387    7,390    0

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    biote Corp.
    By:  

    /s/ Bret Christensen

    Name:   Bret Christensen
    Title:   Chief Executive Officer

    Date: May 18, 2026

    Get the next $BTMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTMD

    DatePrice TargetRatingAnalyst
    8/7/2025$4.00Buy → Neutral
    B. Riley Securities
    12/16/2024Buy
    Craig Hallum
    2/20/2024$9.00Buy
    B. Riley Securities
    2/1/2024Buy
    Jefferies
    More analyst ratings

    $BTMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    biote Corp. downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded biote Corp. from Buy to Neutral and set a new price target of $4.00

    8/7/25 7:36:54 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Craig Hallum initiated coverage on biote Corp.

    Craig Hallum initiated coverage of biote Corp. with a rating of Buy

    12/16/24 8:50:55 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    B. Riley Securities initiated coverage on biote Corp. with a new price target

    B. Riley Securities initiated coverage of biote Corp. with a rating of Buy and set a new price target of $9.00

    2/20/24 6:47:29 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Guines Llc bought $1,461,373 worth of shares (447,714 units at $3.26) (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    5/8/25 7:16:54 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Guines Llc bought $6,371 worth of shares (1,933 units at $3.30) (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    5/2/25 5:12:33 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Guines Llc bought $28,782 worth of shares (8,801 units at $3.27) (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    4/23/25 4:58:23 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Heyer Andrew R

    4 - biote Corp. (0001819253) (Issuer)

    5/14/26 4:10:06 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Morris Debra L converted options into 21,407 shares, increasing direct ownership by 43% to 71,562 units (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    5/13/26 6:17:55 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Director Cone Stephen Mark

    4 - biote Corp. (0001819253) (Issuer)

    5/13/26 6:08:03 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BTMD
    SEC Filings

    View All

    Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer

    Biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company") today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally recognized physician executive, board-certified OB/GYN and reproductive geneticist with more than two decades of experience spanning clinical practice, healthcare quality, academic medicine, innovation, and systems leadership. She joins Biote following senior leadership roles within NYC Health + Hospitals, where she most recently served as Chief Quality Officer for Jacobi Hospital and North Central Bronx Hospital, overseeing quality and safety programs across a large, complex healthcare system serving appro

    6/1/26 8:00:00 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO

    Bret Christensen Stepping Down as CEO for Family and Personal Reasons, Remains a Director Company Reaffirms Full Year 2026 Guidance Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced that Bob Peterson, Chief Financial Officer and Chief Business Officer, has been named Interim Chief Executive Officer and Director, effective June 8, 2026. Bret Christensen is stepping down from his role as Chief Executive Officer and will continue to serve on the Company's Board of Directors. In addition, Marc Beer, Biote's Chairman, will assume the role of Executive Chairman. Commenting

    5/28/26 9:00:00 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Reports First Quarter 2026 Financial Results

    Sales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter 2026 Financial Highlights Revenue of $44.9 million Gross profit margin of 68.9% Net income of $2.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37 in the first quarter of 2025 Adjusted EBITDA1 of $8.7 million and Adjusted EBITDA margin1 of 19.4% Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners

    5/6/26 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Corp. filed SEC Form 8-K: Leadership Update

    8-K - biote Corp. (0001819253) (Filer)

    6/2/26 5:17:02 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 8-K filed by Biote Corp.

    8-K - biote Corp. (0001819253) (Filer)

    5/18/26 4:30:20 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Biote Corp.

    SCHEDULE 13G/A - biote Corp. (0001819253) (Subject)

    5/13/26 4:30:36 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Leadership Updates

    Live Leadership Updates

    View All

    Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer

    Biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company") today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally recognized physician executive, board-certified OB/GYN and reproductive geneticist with more than two decades of experience spanning clinical practice, healthcare quality, academic medicine, innovation, and systems leadership. She joins Biote following senior leadership roles within NYC Health + Hospitals, where she most recently served as Chief Quality Officer for Jacobi Hospital and North Central Bronx Hospital, overseeing quality and safety programs across a large, complex healthcare system serving appro

    6/1/26 8:00:00 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO

    Bret Christensen Stepping Down as CEO for Family and Personal Reasons, Remains a Director Company Reaffirms Full Year 2026 Guidance Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced that Bob Peterson, Chief Financial Officer and Chief Business Officer, has been named Interim Chief Executive Officer and Director, effective June 8, 2026. Bret Christensen is stepping down from his role as Chief Executive Officer and will continue to serve on the Company's Board of Directors. In addition, Marc Beer, Biote's Chairman, will assume the role of Executive Chairman. Commenting

    5/28/26 9:00:00 AM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Announces CEO Retirement and Succession Plan

    Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

    1/30/25 4:10:00 PM ET
    $BTMD
    $HOLX
    $MYGN
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical Electronics
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $BTMD
    Financials

    Live finance-specific insights

    View All

    Biote Reports First Quarter 2026 Financial Results

    Sales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter 2026 Financial Highlights Revenue of $44.9 million Gross profit margin of 68.9% Net income of $2.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37 in the first quarter of 2025 Adjusted EBITDA1 of $8.7 million and Adjusted EBITDA margin1 of 19.4% Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners

    5/6/26 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Schedules First Quarter 2026 Financial Results Release and Conference Call

    biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners' patients, today announced the Company will provide first quarter financial results on Wednesday, May 6, 2026, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be avai

    4/22/26 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Biote Reports Fourth Quarter and Full Year 2025 Financial Results

    Executing efficiently on strategic priorities Continued salesforce expansion to capture large growth opportunity Anticipate a return to procedure revenue growth in the second half of 2026 Fourth Quarter 2025 Financial Highlights Revenue of $46.4 million Gross profit margin of 68.0% Net income of $2.6 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $3.5 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the fourth quarter of 2024 Adjusted EBITDA1 of $11.7 million and Adjusted EBITDA margin1 of 25.2% Full Year 2025 Financial Highlights Revenue of $192.2 million

    3/11/26 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biote Corp.

    SC 13G/A - biote Corp. (0001819253) (Subject)

    11/12/24 4:15:18 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Biote Corp. (Amendment)

    SC 13G/A - biote Corp. (0001819253) (Subject)

    2/14/24 5:17:02 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Biote Corp. (Amendment)

    SC 13G/A - biote Corp. (0001819253) (Subject)

    2/14/24 2:11:05 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care